Optimizerx Corporation (OPRX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook
OptimizeRx is upgraded to 'Buy' due to an improved 2027 growth outlook and an attractive valuation. Q2 2026 saw gross margin rise to 76.5%, marking five consecutive quarters of gains amid a strategic shift to higher-margin offerings. OPRX reaffirmed 2026 guidance: revenue of $95M–$100M and adjusted EBITDA of $21M–$25M.
OptimizeRx Q2 Earnings Call Highlights
OptimizeRx NASDAQ: OPRX reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% from $29.2 million a year earlier, while adjusted EBITDA totaled $4.9 million, management said on its earnings call. The company reaffirmed its full-year revenue outlook of $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million.
OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript
OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript
Optimizerx Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 255 | $1,524.71 | $2,113.95 | $589.24 | 38.65% |
 Point72 Asset Management LP Point72 Asset Management LP | 55,619 | $318,141 | $492,228.15 | $174,087.15 | 54.72% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 45 | $282.04 | $398.25 | $116.21 | 41.2% |
| PA Philip Arnaudov PharVision Advisers LLC | 12,904 | $73,811 | $112,910 | $39,099 | 52.97% |
 Andrew Wiener Samjo Management, LLC | 32,000 | $183,040 | $280,960 | $97,920 | 53.5% |
Optimizerx Corporation (OPRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Optimizerx Corporation ever had a stock split?
Optimizerx Corporation Profile
| Software Industry | Information Technology Sector | Stephen L. Silvestro CEO | NASDAQ (CM) Exchange | 68401U204 CUSIP |
| US Country | 133 Employees | - Last Dividend | 14 May 2018 Last Split | 22 Oct 1996 IPO Date |
Overview
OptimizeRx Corporation is a pioneering digital health technology company, established in 2006 and headquartered in Waltham, Massachusetts. It specializes in facilitating communication between life sciences organizations, healthcare providers, and patients at various crucial points throughout the patient care journey. By leveraging its innovative technology, OptimizeRx Corporation aims to improve patient outcomes and support healthcare providers by delivering timely and relevant treatment information. The company's focus on care-focused engagement stands out in the healthcare technology sector, making it a key player in driving advancements in digital health care solutions.
Products and Services
- Artificial Intelligence-generated Dynamic Audience and Activation Platform:
This platform represents the core of OptimizeRx’s offerings. It employs artificial intelligence to generate dynamic audiences and enable the execution of both traditional and dynamic marketing campaigns. Traditional marketing campaigns can run on OptimizeRx’s proprietary digital point-of-care network, which includes healthcare providers and patients. The more innovative aspect, however, lies in its dynamic marketing campaigns. These campaigns adjust and optimize audiences in real time based on clinical care events, ensuring that healthcare professionals and patients receive the most relevant and timely treatment information. This real-time optimization enhances the effectiveness of communication between pharmaceutical companies, healthcare providers, and patients, ultimately aiming to improve patient care outcomes.
Contact Information
